| Literature DB >> 31057422 |
Angus Li1,2, Yu Sun1, Charles Drummer1, Yifan Lu1, Daohai Yu3, Yan Zhou4, Xinyuan Li1, Simone J Pearson1, Candice Johnson1, Catherine Yu5, William Y Yang1, Kevin Mastascusa1, Xiaohua Jiang1, Jianxin Sun6, Thomas Rogers7, Wenhui Hu1, Hong Wang1, Xiaofeng Yang1,7.
Abstract
Circular RNAs (circRNAs) are non-coding RNAs that form covalently closed continuous loops, and act as gene regulators in physiological and disease conditions. To test our hypothesis that proatherogenic lipid lysophosphatidylcholine (LPC) induce a set of circRNAs in human aortic endothelial cell (HAEC) activation, we performed circRNA analysis by searching our RNA-Seq data from LPC-activated HAECs, and found: (1) LPC induces significant modulation of 77 newly characterized cirRNAs, among which 47 circRNAs (61%) are upregulated; (2) 34 (72%) out of 47 upregulated circRNAs are upregulated when the corresponding mRNAs are downregulated, suggesting that the majority of circRNAs are upregulated presumably via LPC-induced "abnormal splicing" when the canonical splicing for generation of corresponding mRNAs is suppressed; (3) Upregulation of 47 circRNAs is temporally associated with mRNAs-mediated LPC-upregulated cholesterol synthesis-SREBP2 pathway and LPC-downregulated TGF-β pathway; (4) Increase in upstream chromatin long-range interaction sites to circRNA related genes is associated with preferred circRNA generation over canonical splicing for mRNAs, suggesting that shifting chromatin long-range interaction sites from downstream to upstream may promote induction of a list of circRNAs in lysoPC-activated HAECs; (5) Six significantly changed circRNAs may have sponge functions for miRNAs; and (6) 74% significantly changed circRNAs contain open reading frames, suggesting that putative short proteins may interfere with the protein interaction-based signaling. Our findings have demonstrated for the first time that a new set of LPC-induced circRNAs may contribute to homeostasis in LPC-induced HAEC activation. These novel insights may lead to identifications of new therapeutic targets for treating metabolic cardiovascular diseases, inflammations, and cancers.Entities:
Keywords: RNA-Seq; chromatin long–range interaction; circular RNAs; human aortic endothelial cell activation; proatherogenic lipid lysophosphatidylcholine
Year: 2019 PMID: 31057422 PMCID: PMC6482593 DOI: 10.3389/fphys.2019.00433
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1(A) Lysophosphatidylcholine (LPC)-induced top 5% significantly changed circular RNAs (circRNAs) are studied in human aortic endothelial cells (HAECs) in comparison to that of control HAECS. This is a flow chart to outline how we analyzed the 5% top significantly changed circular RNAs from LPC-treated HAECs in comparison to that from control HAECs. (B) The majority (48 out of 51,94.1%) of circRNA expression increases while related mRNA expressions remain constant or decrease. (C) There is no significant differences in exon numbers among circRNA groups. (D) There are no overlaps among the top 10 pathways in the following four groups.
LPC-induced 77 circRNAs in HAECs can be classified into 6 groups based on expression change of circRNAs and corresponding (related) mRNAs.
| Gene ID | Gene | circRNAdb ID | Readnumber (LPC) | Readnumber (Control) | Ratio | Log(2) ratio | FC (mRNA) | Index (circRNA exons) | Exon count | Exon count (genomic) | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| circRNA expression increased, mRNA expression increased ( | |||||||||||
| 23094 | SIPA1L3 | hsa_circ_10577 | 9 | 2 | 4.5 | 2.17 | 1.12 | 11,12 | 2 | 24 | |
| 117583 | PARD3B | N/A | 4 | 1 | 4 | 2 | 1.19 | 4,5,6,7,8,9,10,11, 12,13,14,15 | 12 | 33 | |
| 116840 | CNTROB | hsa_circ_09218 | 4 | 1 | 4 | 2 | 1.11 | 13 | 1 | 22 | |
| circRNA expression decreased, mRNA expression increased ( | |||||||||||
| 2530 | FUT8 | hsa_circ_02544 | 1 | 7 | 0.14 | –2.81 | 1.2 | 3 | 1 | 15 | |
| 768211 | RELL1 | hsa_circ_08846 | 2 | 15 | 0.13 | –2.91 | 1.15 | 6,5,4 | 3 | 8 | |
| 51150 | SDF4 | hsa_circ_21644 | 1 | 9 | 0.11 | –3.17 | 1.15 | 4,3 | 2 | 8 | |
| 64778 | FNDC3B | hsa_circ_15231 | 1 | 15 | 0.07 | –3.91 | 1.13 | 5,6 | 2 | 30 | |
| circRNA expression increased, mRNA expression unchanged ( | |||||||||||
| 55852 | TEX2 | hsa_circ_31354 | 15 | 1 | 15 | 3.91 | 0.98 | 7,6,5 | 3 | 15 | |
| 5820 | PVT1 | hsa_circ_16350 | 8 | 1 | 8 | 3 | 2 | 1 | 9 | ||
| 51232 | CRIM1 | hsa_circ_16396 | 15 | 2 | 7.5 | 2.91 | 1.03 | 2,3,4 | 3 | 22 | |
| 1793 | DOCK1 | hsa_circ_00689 | 7 | 1 | 7 | 2.81 | 1.05 | 2,3,4,5,6,7,8,9,10,11, 12,13,14,15,16,17, 18,19,20,21,22,23 | 22 | 56 | |
| 4670 | HNRNPM | hsa_circ_20744 | 7 | 1 | 7 | 2.81 | 1.01 | 2,3,4,5 | 4 | 16 | |
| 22937 | SCAP | hsa_circ_19380 | 7 | 1 | 7 | 2.81 | 0.94 | 8,7,6,5,4 | 5 | 25 | |
| 9341 | VAMP3 | hsa_circ_18051 | 7 | 1 | 7 | 2.81 | 0.94 | 3,4 | 2 | 5 | |
| N/A | RP11-146B14.1 | N/A | 6 | 1 | 6 | 2.58 | #N/A | 12,13,14,15 | 4 | ||
| 9380 | GRHPR | hsa_circ_03935 | 6 | 1 | 6 | 2.58 | 1.06 | 2,3,4 | 3 | 11 | |
| 27086 | FOXP1 | hsa_circ_19469 | 6 | 1 | 6 | 2.58 | 1.01 | 12,11,10,9,8 | 5 | 32 | |
| 64750 | SMURF2 | hsa_circ_01208 | 5 | 1 | 5 | 2.32 | 1.11 | 10,9,8,7,6 | 5 | 19 | |
| 84456 | L3MBTL3 | N/A | 5 | 1 | 5 | 2.32 | 1.03 | 4,5,6,7,8,9,10,11, 12,13,14,15,16, 17,18,19,20,21 | 18 | 30 | |
| 862 | RUNX1T1 | N/A | 5 | 1 | 5 | 2.32 | 0.99 | 5,4,3,2 | 4 | 20 | |
| 151050 | KANSL1L | hsa_circ_06859 | 5 | 1 | 5 | 2.32 | 0.96 | 4,3,2 | 3 | 23 | |
| 11138 | TBC1D8 | hsa_circ_32540 | 5 | 1 | 5 | 2.32 | 0.94 | 15,14,13,12,11,10 | 6 | 25 | |
| 84328 | LZIC | hsa_circ_31394 | 5 | 1 | 5 | 2.32 | 0.94 | 4,3,2 | 3 | 10 | |
| 23331 | TTC28 | hsa_circ_22261 | 5 | 1 | 5 | 2.32 | 0.93 | 3,2 | 2 | 29 | |
| 1456 | CSNK1G3 | hsa_circ_08140 | 14 | 3 | 4.67 | 2.22 | 0.93 | 2,3,4 | 3 | 18 | |
| 8460 | TPST1 | hsa_circ_22617 | 9 | 2 | 4.5 | 2.17 | 0.98 | 2,3 | 2 | 8 | |
| #N/A | PRKY | hsa_circ_30664 | 4 | 1 | 4 | 2 | N/A | 4,5,6,7 | 4 | 8 | |
| #N/A | PCNXL2 | hsa_circ_10712 | 4 | 1 | 4 | 2 | N/A | 23,22 | 2 | ||
| 1523 | CUX1 | hsa_circ_12403 | 8 | 2 | 4 | 2 | 1.11 | 21 | 1 | 34 | |
| 9701 | PPP6R2 | hsa_circ_07544 | 4 | 1 | 4 | 2 | 1.11 | 2,3 | 2 | 29 | |
| 54919 | DNAAF5 | N/A | 4 | 1 | 4 | 2 | 1.1 | 9,10,11 | 3 | 14 | |
| 84293 | FAM213A | N/A | 4 | 1 | 4 | 2 | 1.06 | 2,3,4 | 3 | 9 | |
| 7813 | EVI5 | hsa_circ_11187 | 4 | 1 | 4 | 2 | 1.04 | 19,18,17 | 3 | 30 | |
| 81608 | FIP1L1 | hsa_circ_18069 | 4 | 1 | 4 | 2 | 1.02 | 11,12,13 | 3 | 19 | |
| 51295 | ECSIT | hsa_circ_00599 | 4 | 1 | 4 | 2 | 1 | 4,3 | 2 | 9 | |
| 152002 | XXYLT1 | hsa_circ_02143 | 4 | 1 | 4 | 2 | 1 | 3,2 | 2 | 11 | |
| 6310 | ATXN1 | hsa_circ_13397 | 4 | 1 | 4 | 2 | 0.99 | 8 | 1 | 11 | |
| 1024 | CDK8 | hsa_circ_27078 | 4 | 1 | 4 | 2 | 0.98 | 10,11,12 | 3 | 14 | |
| 6259 | RYK | hsa_circ_26048 | 4 | 1 | 4 | 2 | 0.98 | 13,12,11,10,9,8,7 | 7 | 15 | |
| 92 | ACVR2A | hsa_circ_04751 | 4 | 1 | 4 | 2 | 0.98 | 2,3,4 | 3 | 12 | |
| 22828 | SCAF8 | hsa_circ_06913 | 4 | 1 | 4 | 2 | 0.98 | 2,3,4,5,6 | 5 | 22 | |
| 29086 | BABAM1 | hsa_circ_04303 | 4 | 1 | 4 | 2 | 0.96 | 7,8 | 2 | 9 | |
| 23244 | PDS5A | hsa_circ_29001 | 4 | 1 | 4 | 2 | 0.95 | 21,20,19,18,17 | 5 | 36 | |
| 7443 | VRK1 | hsa_circ_08594 | 4 | 1 | 4 | 2 | 0.94 | 2,3,4,5,6,7,8,9,10,11 | 10 | 15 | |
| 8826 | IQGAP1 | hsa_circ_10932 | 4 | 1 | 4 | 2 | 0.93 | 6,7,8,9 | 4 | 39 | |
| circRNA expression decreased, mRNA expression unchanged ( | |||||||||||
| 23362 | PSD3 | hsa_circ_02851 | 1 | 7 | 0.14 | –2.81 | 1.05 | 8,7,6,5 | 4 | 29 | |
| 55833 | UBAP2 | hsa_circ_30156 | 1 | 7 | 0.14 | –2.81 | 0.94 | 12,11,10,9 | 4 | 30 | |
| 10443 | N4BP2L2 | hsa_circ_12240 | 1 | 7 | 0.14 | –2.81 | 0.93 | 6,5,4,3 | 4 | 22 | |
| 6904 | TBCD | hsa_circ_00754 | 2 | 15 | 0.13 | –2.91 | 1.05 | 14,15,16,17,18,19 | 6 | 61 | |
| 5747 | PTK2 | hsa_circ_23485 | 2 | 15 | 0.13 | –2.91 | 1.03 | 5,4,3 | 3 | 44 | |
| 23603 | CORO1C | hsa_circ_01619 | 1 | 9 | 0.11 | –3.17 | 1.06 | 8,7 | 2 | 20 | |
| 5917 | RARS | hsa_circ_21209 | 1 | 9 | 0.11 | –3.17 | 1.01 | 2,3,4,5 | 4 | 15 | |
| 11174 | ADAMTS6 | hsa_circ_28538 | 3 | 29 | 0.1 | –3.27 | 1.05 | 7,6,5,4,3,2 | 6 | 33 | |
| 22955 | SCMH1 | hsa_circ_12377 | 1 | 10 | 0.1 | –3.32 | 1.09 | 10,9 | 2 | 22 | |
| 51306 | FAM13B | hsa_circ_11413 | 1 | 10 | 0.1 | –3.32 | 1.01 | 10,9,8 | 3 | 30 | |
| 2050 | EPHB4 | hsa_circ_08510 | 1 | 10 | 0.1 | –3.32 | 1 | 12,11 | 2 | 17 | |
| 444 | ASPH | hsa_circ_10828 | 1 | 11 | 0.09 | –3.46 | 1 | 3,2 | 2 | 33 | |
| 57488 | ESYT2 | hsa_circ_25060 | 1 | 11 | 0.09 | –3.46 | 0.95 | 13,12,11,10,9 | 5 | 26 | |
| 10905 | MAN1A2 | hsa_circ_02643 | 1 | 15 | 0.07 | –3.91 | 1.06 | 2,3,4,5 | 4 | 14 | |
| 50807 | ASAP1 | hsa_circ_09642 | 1 | 15 | 0.07 | –3.91 | 0.93 | 14,13,12,11,10,9 | 6 | 37 | |
| circRNA expression increased, mRNA expression decreased ( | |||||||||||
| 4649 | MYO9A | N/A | 8 | 1 | 8 | 3 | 0.75 | 39,38,37,36,35,34, 33,32,31,30,29,28 | 12 | 48 | |
| 10564 | ARFGEF2 | N/A | 5 | 1 | 5 | 2.32 | 0.91 | 5,6,7 | 3 | 39 | |
| 51444 | RNF138 | hsa_circ_01057 | 5 | 1 | 5 | 2.32 | 0.9 | 3,4 | 2 | 8 | |
| 152006 | RNF38 | hsa_circ_32756 | 5 | 1 | 5 | 2.32 | 0.79 | 4,3 | 2 | 19 | |
| 23047 | PDS5B | hsa_circ_01546 | 4 | 1 | 4 | 2 | 0.91 | 2,3 | 2 | 38 | |
| 55719 | SLF2 | N/A | 4 | 1 | 4 | 2 | 0.9 | 5,6 | 2 | 21 | |
| 55247 | NEIL3 | hsa_circ_00262 | 4 | 1 | 4 | 2 | 0.84 | 8,9 | 2 | 10 | |
| 56886 | UGGT1 | N/A | 4 | 1 | 4 | 2 | 0.78 | 2,3,4,5,6,7,8,9,10, 11,12,13,14,15,16 | 15 | 44 | |
| 23499 | MACF1 | N/A | 4 | 1 | 4 | 2 | 0.68 | 42,43,44,45,46,47, 48,49,50,51,52 | 11 | 111 | |
| 11123 | RCAN3 | hsa_circ_22201 | 4 | 1 | 4 | 2 | 0.67 | 2 | 1 | 7 | |
| circRNA expression decreased, mRNA expression decreased ( | |||||||||||
| 659 | BMPR2 | hsa_circ_06837 | 1 | 7 | 0.14 | –2.81 | 0.84 | 2,3 | 2 | 13 | |
| 23253 | ANKRD12 | hsa_circ_31497 | 1 | 7 | 0.14 | –2.81 | 0.78 | 2,3,4,5,6,7 | 6 | 18 | |
| 10725 | NFAT5 | hsa_circ_16704 | 1 | 8 | 0.13 | –3 | 0.64 | 15 | 1 | 19 | |
| 26057 | ANKRD17 | hsa_circ_01636 | 1 | 9 | 0.11 | –3.17 | 0.91 | 29 | 1 | 37 | |
| 55125 | CEP192 | hsa_circ_26363 | 1 | 9 | 0.11 | –3.17 | 0.85 | 2,3,4,5,6,7,8,9 | 8 | 46 | |
| 121512 | FGD4 | hsa_circ_21030 | 1 | 9 | 0.11 | –3.17 | 0.85 | 5,6,7,8,9,10 | 6 | 27 | |
| 22836 | RHOBTB3 | hsa_circ_19124 | 1 | 17 | 0.06 | –4.09 | 0.91 | 6,7 | 2 | 14 | |
LysoPC does not significantly modulate the expressions of housekeeping mRNAs in human aortic endothelial cells (HAECs), suggesting that the RNA-Seq experiments in HAECs treated with lysoPC were well performed.
| Housekeeping genes | Fold change |
| C1orf43 | 0.97 |
| CHMP2A | 1 |
| GADPH | 1 |
| EMC7 | 0.98 |
| GPI | 1 |
| PSMB2 | 0.98 |
| PSMB4 | 1.02 |
| RAB7A | 0.98 |
| SNRPD3 | 1 |
| VPS29 | 1.04 |
There are no overlaps among the top 10 pathways in the following four groups #, suggesting that the functions of circRNAs-related mRNAs do not participate in LPC-induced human aortic endothelial cell activation.
| Number | LPC upregulated mRNAs (promoting endothelial activation, PMID) | CircRNA increased and mRNA unchanged genes (inflammation, PMID) |
|---|---|---|
| 1 | Superpathway of cholesterol biosynthesis (HAEC activation, 29371247) | Pyridoxal 5′-phosphate salvage pathway (neurological pathologies, 22201923) |
| 2 | Cholesterol biosynthesis I | Fcγ Receptor-mediated phagocytosis in macrophages and monocytes (immune responses, 28117787) |
| 3 | Cholesterol biosynthesis II (via 24,25-dihydrolanosterol) | TGF-β signaling (anti-inflammation, 22438968) |
| 4 | Cholesterol biosynthesis III (via Desmosterol) | Salvage pathways of pyrimidine ribonucleotides (repair and inflammatory signal, 28053879) |
| 5 | Granulocyte adhesion and diapedesis | Epithelial adherens junction signaling (epithelial cell migration, 30010460) |
| 6 | Hepatic fibrosis/hepatic stellate cell activation | Wnt/β-catenin signaling (immune response, 25136145) |
| 7 | Role of macrophages, fibroblasts, and endothelial Cells in rheumatoid arthritis | Actin cytoskeleton signaling (immune response, 30274167) |
| 8 | Role of IL-17F in allergic inflammatory airway diseases | Cell cycle control of chromosomal replication (immune response, 29908233) |
| 9 | Agranulocyte adhesion and diapedesis | Unfolded protein response (inflammatory response, 30278941) |
| 10 | p38 MAPK signaling | Remodeling of epithelial adherens junctions (epithelial cell migration, 30010460) |
| 1 | Ephrin B signaling | Role of osteoblasts, osteoclasts, and chondrocytes in rheumatoid arthritis |
| 2 | FAK signaling | Neuroinflammation signaling pathway |
| 3 | Axonal guidance signaling | Cardiomyocyte differentiation via BMP receptors |
| 4 | Ephrin receptor signaling | April mediated signaling |
| 5 | Integrin signaling | B Cell activating factor signaling |
| 6 | IL-15 production | Wnt/Ca+ pathway |
| 7 | tRNA charging | Netrin signaling |
| 8 | Semaphorin signaling in neurons | BMP signaling pathway |
| 9 | Ephrin A signaling | Regulation of IL-2 expression in activated and anergic T lymphocytes |
| 10 | Regulation of cellular mechanics by calpain protease | Factors promoting cardiogenesis in vertebrates |
FIGURE 2(A) Pre-splicing RNA transcripts with reverse complementary matches in flanking intron sequences tend to favor circRNA biogenesis, (B) There is no significant difference in bitscore between groups when non-parametric testing is performed.
53 out of 77 (68.8%) circRNAs have significant homologies between flanking introns, which may facilitate chromatin looping and circRNA generation.
| Gene | circRNAdb ID | % identity | Bitscore | |
|---|---|---|---|---|
| circRNA expression increased, mRNA expression increased | ||||
| PARD3B | N/A | 98.44 | 0.00 | 4617 |
| SIPA1L3 | hsa_circ_10577 | 90.24 | 0.00 | 374 |
| circRNA expression decreased, mRNA expression increased | ||||
| FUT8 | hsa_circ_02544 | 93.17 | 0.00 | 429 |
| RELL1 | hsa_circ_08846 | 88.03 | 0.00 | 335 |
| FNDC3B | hsa_circ_15231 | 84.59 | 0.00 | 311 |
| circRNA expression increased, mRNA expression unchanged | ||||
| PCNXL2 | hsa_circ_10712 | 98.65 | 0.00 | 525 |
| RUNX1T1 | hsa_circ_02162 | 89.74 | 0.00 | 427 |
| DOCK1 | hsa_circ_00689 | 89.61 | 0.00 | 387 |
| TTC28 | hsa_circ_22261 | 89.6 | 0.00 | 375 |
| ATXN1 | hsa_circ_13397 | 89.45 | 0.00 | 300 |
| XXYLT1 | hsa_circ_02143 | 89.26 | 0.00 | 521 |
| ECSIT | hsa_circ_00599 | 88.63 | 0.00 | 361 |
| CUX1 | hsa_circ_12403 | 87.25 | 0.00 | 333 |
| EVI5 | hsa_circ_11187 | 86.53 | 0.00 | 363 |
| SMURF2 | hsa_circ_01208 | 86.23 | 0.00 | 324 |
| IQGAP1 | hsa_circ_10932 | 86.13 | 0.00 | 291 |
| TEX2 | hsa_circ_31354 | 85.26 | 0.00 | 316 |
| TBC1D8 | hsa_circ_32540 | 84.04 | 0.00 | 263 |
| TPST1 | hsa_circ_22617 | 83.83 | 0.00 | 560 |
| LZIC | hsa_circ_31394 | 83.55 | 0.00 | 278 |
| SCAF8 | hsa_circ_06913 | 83.05 | 0.00 | 261 |
| KANSL1L | hsa_circ_06859 | 82.95 | 0.00 | 191 |
| VRK1 | hsa_circ_08594 | 82.95 | 0.00 | 115 |
| DNAAF5 | N/A | 82.87 | 0.00 | 254 |
| PDS5A | hsa_circ_29001 | 82.68 | 0.00 | 257 |
| PPP6R2 | hsa_circ_07544 | 82.34 | 0.00 | 499 |
| ACVR2A | hsa_circ_04751 | 81.88 | 0.00 | 255 |
| VAMP3 | hsa_circ_18051 | 81.76 | 0.00 | 250 |
| PRKY | hsa_circ_30664 | 81.66 | 0.00 | 230 |
| CSNK1G3 | hsa_circ_08140 | 80.89 | 0.00 | 226 |
| PVT1 | hsa_circ_16350 | 76.23 | 0.00 | 619 |
| circRNA expression decreased, mRNA expression unchanged | ||||
| FAM13B | hsa_circ_11413 | 89.9 | 0.00 | 379 |
| SCMH1 | hsa_circ_12377 | 89.74 | 0.00 | 387 |
| N4BP2L2 | hsa_circ_12240 | 88.45 | 0.00 | 363 |
| ADAMTS6 | hsa_circ_28538 | 88.41 | 0.00 | 353 |
| PSD3 | hsa_circ_02851 | 87.66 | 0.00 | 351 |
| UBAP2 | hsa_circ_30156 | 87.63 | 0.00 | 326 |
| PTK2 | hsa_circ_23485 | 85.49 | 0.00 | 396 |
| ASAP1 | hsa_circ_09642 | 84.95 | 0.00 | 294 |
| MAN1A2 | hsa_circ_02643 | 84.03 | 0.00 | 272 |
| EPHB4 | hsa_circ_08510 | 82.08 | 0.00 | 257 |
| circRNA expression increased, mRNA expression decreased | ||||
| UGGT1 | N/A | 87.2 | 0.00 | 326 |
| RNF38 | hsa_circ_32756 | 86.81 | 0.00 | 318 |
| RNF138 | hsa_circ_01057 | 86.3 | 0.00 | 315 |
| SLF2 | N/A | 85.76 | 0.00 | 315 |
| RCAN3 | hsa_circ_22201 | 83.84 | 0.00 | 278 |
| PDS5B | hsa_circ_01546 | 82.06 | 0.00 | 254 |
| circRNA expression decreased, mRNA expression decreased | ||||
| RHOBTB3 | hsa_circ_19124 | 90.64 | 0.00 | 392 |
| ANKRD12 | hsa_circ_31497 | 85.86 | 0.00 | 313 |
| ANKRD17 | hsa_circ_01636 | 85.37 | 0.00 | 296 |
| CEP192 | hsa_circ_26363 | 84.76 | 0.00 | 307 |
| BMPR2 | hsa_circ_06837 | 81.99 | 0.00 | 503 |
| FGD4 | hsa_circ_21030 | 78.65 | 0.00 | 115 |
Seventeen spliceosome genes out of approximately 80 proteins have fold changes outside a housekeeping gene-determined 95 percent confidence interval in RNA-Seq data.
| Gene | FC |
|---|---|
| FUS | 0.68 |
| PCBP2 | 0.68 |
| RBM7 | 0.77 |
| THOC1 | 0.82 |
| LSM8 | 0.83 |
| PCBP1 | 0.87 |
| RBM10 | 1.11 |
| EIF4A3 | 1.12 |
| CCDC130 | 1.12 |
| RBM42 | 1.13 |
| DGCR14 | 1.13 |
| MFAP1 | 1.18 |
| PUF60 | 1.18 |
| THOC3 | 1.20 |
| LSM6 | 1.21 |
| RNF113A | 1.24 |
| FAM50B | 1.25 |
FIGURE 3LPC modulates the expressions of spliceosome components and may facilitate the generation of circRNAs.
FIGURE 4(A) Chromatin long range interaction may regulate the expressions of circRNAs-related genes via forming chromatin loops. (B) Loosely packed chromatin regions either upstream or downstream from circRNAs related gene promoters may differentially prefer back splicing to generate circRNAs to canonical splicing to generate mRNAs. (C) Shifting chromatin long-range interaction sites from downstream to upstream may promotes a list of circular RNAs; and in contrast, shifting chromatin long-range interaction sites from upstream to downstream promotes induction of a list of mRNAs. The data were collected from the experimental data deposited in the 4DGenome database (https://4dgenome.research.chop.edu) containing the data from human umbilical vein endothelial cells (HUVECs).
Six circRNAs demonstrate miRNA sponging activities.
| Gene | circRNAdb ID | miRNA sponged | Readnumber (LPC) | Readnumber (control) | Ratio | Function of microRNA | PMID |
|---|---|---|---|---|---|---|---|
| PVT1 | hsa_circ_16350 | miR-125 | 8 | 1 | 8 | Promote regeneration/repair | 29461585 |
| UBAP2 | hsa_circ_30156 | miR-143 | 1 | 7 | 0.14 | Inhibit autophage/promote inflammation | 29562274 |
| VAMP3 | hsa_circ_18051 | miR-1272 | 7 | 1 | 7 | T cell differentiation | 26941729 |
| VRK1 | hsa_circ_08594 | miR-153 | 4 | 1 | 4 | Inhibit migration/invasion | 29113423 |
| FGD4 | hsa_circ_21030 | miR-515-5p | 1 | 9 | 0.11 | Decrease in atopic eczema | 17622355 |
| DOCK1 | hsa_circ_00689 | miR-196a-5p | 7 | 1 | 7 | Delay lymph node metastasis | 29434944 |
FIGURE 5(A) CircRNA has the potential role to inhibit type 2 diabetes mellitus (T2DM)by sponging miRl43 and preventing miRl43 from binding to oxysterol-binding protein-related protein 8 (ORP8) ˆuntranslated region (3′UTR). (B) Upregulated circRNAs sponge miRNAs involved in both pro- and anti-inflammatory pathways. (C) Downregulated circRNAs sponge miRNAs are involved with both pro-inflammatory and anti-inflammatory pathways. (D) One pathway is overlapped in the sponged microRNAs between upregulated and downregulated circRNAs.
All but one circRNA open reading frames with significant BLAST matches encode peptides from the same gene as their corresponding mRNAs.
| Gene | circRNAdb ID | Accession | % ID | Same translation as mRNA? | |
|---|---|---|---|---|---|
| Near-perfect overlap with known sequences | |||||
| VAMP3 | hsa_circ_18051 | XP_016858330 | 100 | 0.00 | Yes |
| DOCK1 | hsa_circ_00689 | Q14185 | 100 | 0.00 | Yes |
| HNRNPM | hsa_circ_20744 | BAG57075 | 100 | 0.00 | Yes |
| FOXP1 | hsa_circ_19469 | BAC11065 | 100 | 0.00 | Yes |
| TBC1D8 | hsa_circ_32540 | BAA76517 | 100 | 0.00 | Yes |
| KANSL1L | hsa_circ_06859 | XP_011509011 | 100 | 0.00 | Yes |
| RUNX1T1 | hsa_circ_02162 | AAB34820 | 100 | 0.00 | Yes |
| CSNK1G3 | hsa_circ_08140 | XP_016864559 | 100 | 0.00 | Yes |
| TPST1 | hsa_circ_22617 | XP_011514936 | 100 | 0.00 | Yes |
| RCAN3 | hsa_circ_22201 | NP_001238914 | 100 | 0.00 | Yes |
| NEIL3 | hsa_circ_00262 | Q8TAT5 | 100 | 0.00 | Yes |
| PPP6R2 | hsa_circ_07544 | EAW73534 | 100 | 0.00 | Yes |
| VRK1 | hsa_circ_08594 | 2LAV_A | 100 | 0.00 | Yes |
| BABAM1 | hsa_circ_04303 | BAG61451 | 100 | 0.00 | Yes |
| RYK | hsa_circ_26048 | AAH21700 | 100 | 0.00 | Yes |
| ATXN1 | hsa_circ_13397 | NP_000323 | 100 | 0.00 | Yes |
| ACVR2A | hsa_circ_04751 | AAH67417 | 100 | 0.00 | Yes |
| PRKY | hsa_circ_30664 | O43930 | 100 | 0.00 | Yes |
| UBAP2 | hsa_circ_30156 | BAG64527 | 100 | 0.00 | Yes |
| RELL1 | hsa_circ_08846 | XP_016864079 | 100 | 0.00 | Yes |
| NFAT5 | hsa_circ_16704 | XP_016878362 | 100 | 0.00 | Yes |
| CEP192 | hsa_circ_26363 | XP_016881293 | 100 | 0.00 | Yes |
| SDF4 | hsa_circ_21644 | XP_011539858 | 100 | 0.00 | Yes |
| CORO1C | hsa_circ_01619 | BAH14436 | 100 | 0.00 | Yes |
| ADAMTS6 | hsa_circ_28538 | XP_011541429 | 100 | 0.00 | Yes |
| ASAP1 | hsa_circ_09642 | CAD97831 | 100 | 0.00 | Yes |
| MAN1A2 | hsa_circ_02643 | XP_016855604 | 100 | 0.00 | Yes |
| ANKRD17 | hsa_circ_01636 | XP_016863500 | 99.796 | 0.00 | Yes |
| ANKRD12 | hsa_circ_31497 | BAB15014 | 99.683 | 0.00 | Yes |
| CRIM1 | hsa_circ_16396 | XP_016859748 | 99.448 | 0.00 | Yes |
| PSD3 | hsa_circ_02851 | XP_016868754 | 99.333 | 0.00 | Yes |
| PDS5B | hsa_circ_01546 | AAH70274 | 99.048 | 0.00 | Yes |
| FNDC3B | hsa_circ_15231 | EAW78473 | 98.864 | 0.00 | Yes |
| FUT8 | hsa_circ_02544 | BAA92858 | 98.551 | 0.00 | Yes |
| PCNXL2 | hsa_circ_10712 | BAG51507 | 98.387 | 0.00 | Yes |
| RHOBTB3 | hsa_circ_19124 | EAW96050 | 98.148 | 0.00 | Yes |
| PTK2 | hsa_circ_23485 | NP_001339677 | 98.052 | 0.00 | Yes |
| SCAP | hsa_circ_19380 | EAW64826 | 97.5 | 0.00 | Yes |
| EPHB4 | hsa_circ_08510 | 4AW5_A | 97.5 | 0.00 | Yes |
| IQGAP1 | hsa_circ_10932 | AAH05906 | 97.458 | 0.00 | Yes |
| XXYLT1 | hsa_circ_02143 | XP_005269343 | 97.403 | 0.00 | Yes |
| SMURF2 | hsa_circ_01208 | EAW94194 | 97.03 | 0.00 | Yes |
| CNTROB | hsa_circ_09218 | XP_016879630 | 97.015 | 0.00 | Yes |
| LZIC | hsa_circ_31394 | NP_001303904 | 96.97 | 0.00 | Yes |
| TTC28 | hsa_circ_22261 | XP_011528324 | 96.947 | 0.00 | Yes |
| PVT1 | hsa_circ_16350 | EAW92103 | 95.918 | 0.00 | No (non-coding gene) |
| FAM13B | hsa_circ_11413 | XP_016865040 | 87.786 | 0.00 | Yes |
| N4BP2L2 | hsa_circ_12240 | EAX08513 | 78.261 | 0.00 | Yes (fragment of same gene) |
| Partial overlap with known sequences | |||||
| BMPR2 | hsa_circ_06837 | NP_057675 | 56 | 3.10 | |
| ESYT2 | hsa_circ_25060 | EAW95833 | 48 | 3.20 | |
| GRHPR | hsa_circ_03935 | EAW60274 | 39.286 | 3.00 | |
| No overlap with known sequences | |||||
| RNF38 | hsa_circ_32756 | ||||
| SIPA1L3 | hsa_circ_10577 | ||||
| SCAF8 | hsa_circ_06913 | ||||
| CDK8 | hsa_circ_27078 | ||||
| ECSIT | hsa_circ_00599 | ||||
| FGD4 | hsa_circ_21030 | ||||
FIGURE 6One example of potential disruption of protein–protein interactions by circRNA encoded short peptides is demonstrated.
75 of 77 circRNA-related genes have numerous interactions with other proteins, suggesting that functional interactions between the circRNAs-related proteins and their interaction proteins may be disrupted by circRNA-encoded short peptides.
| Gene name | circRNAdb ID | Interactions |
|---|---|---|
| TEX2 | hsa_circ_31354 | 7 |
| MYO9A | N/A | 27 |
| PVT1 | hsa_circ_16350 | 2 |
| CRIM1 | hsa_circ_16396 | 3 |
| VAMP3 | hsa_circ_18051 | 74 |
| DOCK1 | hsa_circ_00689 | 37 |
| SCAP | hsa_circ_19380 | 29 |
| HNRNPM | hsa_circ_20744 | 341 |
| GRHPR | hsa_circ_03935 | 34 |
| FOXP1 | hsa_circ_19469 | 47 |
| RP11-146B14.1 | N/A | N/A |
| RNF38 | hsa_circ_32756 | 17 |
| SMURF2 | hsa_circ_01208 | 201 |
| ARFGEF2 | N/A | 53 |
| RNF138 | hsa_circ_01057 | 45 |
| TTC28 | hsa_circ_22261 | 25 |
| LZIC | hsa_circ_31394 | 13 |
| L3MBTL3 | N/A | 38 |
| TBC1D8 | hsa_circ_32540 | 6 |
| KANSL1L | hsa_circ_06859 | 0 |
| RUNX1T1 | hsa_circ_02162 | 96 |
| CSNK1G3 | hsa_circ_08140 | 38 |
| SIPA1L3 | hsa_circ_10577 | 39 |
| TPST1 | hsa_circ_22617 | 13 |
| MACF1 | N/A | 85 |
| RCAN3 | hsa_circ_22201 | 14 |
| UGGT1 | N/A | 65 |
| PARD3B | N/A | 7 |
| NEIL3 | hsa_circ_00262 | 19 |
| CNTROB | hsa_circ_09218 | 123 |
| SLF2 | N/A | 9 |
| PDS5B | hsa_circ_01546 | 54 |
| CUX1 | hsa_circ_12403 | 69 |
| DNAAF5 | N/A | 66 |
| IQGAP1 | hsa_circ_10932 | 294 |
| PPP6R2 | hsa_circ_07544 | 69 |
| VRK1 | hsa_circ_08594 | 34 |
| PDS5A | hsa_circ_29001 | 76 |
| BABAM1 | hsa_circ_04303 | 67 |
| FAM213A | N/A | 23 |
| EVI5 | hsa_circ_11187 | 18 |
| SCAF8 | hsa_circ_06913 | 22 |
| RYK | hsa_circ_26048 | 93 |
| FIP1L1 | hsa_circ_18069 | 81 |
| CDK8 | hsa_circ_27078 | 120 |
| ATXN1 | hsa_circ_13397 | 416 |
| ACVR2A | hsa_circ_04751 | 48 |
| ECSIT | hsa_circ_00599 | 117 |
| XXYLT1 | hsa_circ_02143 | 10 |
| PRKY | hsa_circ_30664 | 8 |
| PCNXL2 | hsa_circ_10712 | 3 |
| ANKRD12 | hsa_circ_31497 | 17 |
| BMPR2 | hsa_circ_06837 | 99 |
| N4BP2L2 | hsa_circ_12240 | 29 |
| UBAP2 | hsa_circ_30156 | 34 |
| PSD3 | hsa_circ_02851 | 8 |
| FUT8 | hsa_circ_02544 | 30 |
| RELL1 | hsa_circ_08846 | 19 |
| TBCD | hsa_circ_00754 | 64 |
| PTK2 | hsa_circ_23485 | 225 |
| NFAT5 | hsa_circ_16704 | 10 |
| FGD4 | hsa_circ_21030 | 5 |
| CEP192 | hsa_circ_26363 | 78 |
| SDF4 | hsa_circ_21644 | 92 |
| ANKRD17 | hsa_circ_01636 | 40 |
| CORO1C | hsa_circ_01619 | 109 |
| RARS | hsa_circ_21209 | 146 |
| ADAMTS6 | hsa_circ_28538 | 2 |
| SCMH1 | hsa_circ_12377 | 41 |
| FAM13B | hsa_circ_11413 | 6 |
| EPHB4 | hsa_circ_08510 | 30 |
| ESYT2 | hsa_circ_25060 | 34 |
| ASPH | hsa_circ_10828 | 44 |
| FNDC3B | hsa_circ_15231 | 12 |
| ASAP1 | hsa_circ_09642 | 44 |
| MAN1A2 | hsa_circ_02643 | 17 |
| RHOBTB3 | hsa_circ_19124 | 35 |
FIGURE 7A new working model: Proatherogenic lipid, LPC, induces the upregulation of a group of circular RNAs in human aortic endothelial cells, which may be generated by three mechanisms and play homeostatic functions via three effector mechanisms.